terican

Last verified · v1.0

Calculator · health

Eortc Bladder Cancer Risk Calculator

Estimate NMIBC recurrence and progression probability using the validated EORTC scoring system based on 6 key clinical and pathological factors.

FreeInstantNo signupOpen source

Inputs

Estimated Risk

—

Explain my result

0/3 free

Get a plain-English breakdown of your result with practical next steps.

Estimated Risk—

The formula

How the
result is
computed.

EORTC Bladder Cancer Risk Calculator: Methodology and Clinical Framework

The EORTC (European Organisation for Research and Treatment of Cancer) bladder cancer risk calculator quantifies the probability of tumor recurrence and disease progression in patients diagnosed with non-muscle-invasive bladder cancer (NMIBC). The tool applies a validated weighted scoring system derived from a landmark multicenter analysis of 2,596 patients enrolled across seven EORTC clinical trials, representing one of the most rigorously validated risk stratification instruments in uro-oncology.

Scientific Foundation

The scoring model was published by Sylvester RJ et al. (2006) and is formally endorsed by the European Association of Urology (EAU) Guidelines on Non-Muscle Invasive Bladder Cancer. The EORTC methodology assigns integer weights to six clinicopathological variables, producing two independent scores: a Recurrence Score (0-17 points) and a Progression Score (0-23 points). Each score maps to a specific probability of an adverse outcome at one year and five years post-treatment.

The Scoring Formula

The composite score is calculated as the weighted sum of all factor values: Score = ∑(wi × xi), where wi represents the EORTC-assigned weight for clinical factor i and xi represents the categorical value of that factor for the individual patient. Separate weight sets govern the recurrence and progression models, reflecting the distinct biological drivers of each outcome.

Scoring Variables and Weights

  • Number of Tumors: A single tumor scores 0 points; 2-7 tumors score 3 points in both models; eight or more tumors score 6 points for recurrence and 3 for progression.
  • Tumor Size: Tumors smaller than 3 cm score 0; tumors 3 cm or larger score 3 points in both the recurrence and progression models.
  • Prior Recurrence Rate: Primary presentation scores 0; a recurrence rate of one episode per year or fewer scores 2 in both models; more than one recurrence per year scores 4 for recurrence and 2 for progression.
  • T Category: Stage Ta tumors score 0; T1 tumors score 1 point for recurrence and 4 points for progression, reflecting the substantially higher malignant potential associated with lamina propria invasion.
  • Concomitant Carcinoma in Situ (CIS): Absence of CIS scores 0; presence scores 1 for recurrence and 6 for progression, the single highest weight in the progression model, underscoring the aggressive biology of flat high-grade lesions.
  • WHO 1973 Grade: Grade 1 scores 0 in both models; Grade 2 scores 1 for recurrence and 0 for progression; Grade 3 scores 2 for recurrence and 5 for progression.

Risk Category Stratification

Recurrence scores stratify into four clinical risk categories with corresponding probability estimates derived from the original EORTC trial dataset:

  • Score 0 (Low Risk): Approximately 15% one-year and 31% five-year recurrence probability.
  • Score 1-4 (Intermediate Risk): Approximately 24% at one year and 46% at five years.
  • Score 5-9 (High Risk): Approximately 38% at one year and 62% at five years.
  • Score 10-17 (Very High Risk): Approximately 61% at one year and 78% at five years.

Progression scores map analogously: Score 0 carries approximately 0.2% one-year and 0.8% five-year progression risk; Score 2-6 approximately 1% and 6%; Score 7-13 approximately 5% and 17%; Score 14-23 approximately 17% and 45%.

Clinical Application Example

A patient presenting with three bladder tumors each under 3 cm (recurrence score +3), a prior recurrence rate below one episode per year (+2), staged T1 (+1), no concomitant CIS (+0), and WHO Grade 2 histology (+1) accumulates a recurrence score of 7. This places the patient in the high-risk category with an estimated 38% one-year recurrence probability, supporting intensified three-month surveillance cystoscopy intervals and consideration of full-course BCG immunotherapy per EAU guidelines.

Limitations and Clinical Context

The EORTC model was built on trial populations predating contemporary BCG maintenance protocols and does not incorporate molecular biomarkers, variant urothelial histology, or surgical quality metrics from the initial transurethral resection. External validation studies report moderate predictive accuracy, with c-statistics typically in the 0.60-0.65 range. Clinicians should interpret scores alongside multidisciplinary tumor board input, patient comorbidities, and individual treatment history. The EORTC bladder cancer calculator functions as a validated decision-support instrument, not a substitute for clinical judgment.

Reference

Frequently asked questions

What is the EORTC bladder cancer risk calculator used for?
The EORTC bladder cancer risk calculator estimates the probability of tumor recurrence and disease progression in patients with non-muscle-invasive bladder cancer (NMIBC). Urologists use the tool to stratify patients into low, intermediate, high, or very high risk categories, directly informing decisions about surveillance cystoscopy frequency, intravesical therapy selection such as BCG or mitomycin C, and whether early radical cystectomy is warranted in very-high-risk cases.
How is the EORTC recurrence score different from the progression score?
The EORTC system generates two independent scores using different weighting coefficients applied to the same six clinical variables. The recurrence score (0-17 points) predicts tumor regrowth after complete transurethral resection, while the progression score (0-23 points) estimates the likelihood of disease advancing to muscle-invasive bladder cancer. Concomitant carcinoma in situ and T1 staging receive substantially higher weights in the progression model because these features are the strongest independent predictors of upstaging to muscle-invasive disease.
Which clinical factors increase the EORTC bladder cancer score the most?
In the recurrence model, having eight or more tumors contributes the maximum 6 points, while a prior recurrence rate exceeding one episode per year adds 4 points. In the progression model, concomitant carcinoma in situ (CIS) adds 6 points and T1 staging adds 4 points. WHO Grade 3 histology contributes 5 points toward progression, making high-grade T1 disease with concurrent CIS the highest-risk combination a patient can present with under the EORTC framework.
How does the EORTC score guide bladder cancer treatment decisions?
European Association of Urology (EAU) guidelines tie treatment intensity directly to EORTC risk categories. Low-risk patients receive a single immediate postoperative instillation of intravesical chemotherapy and annual surveillance cystoscopy. Intermediate-risk patients undergo one year of intravesical chemotherapy. High and very-high-risk patients require BCG induction followed by one to three years of maintenance therapy, with cystoscopy scheduled every three months for the first two years, transitioning to biannual and then annual surveillance thereafter.
Is the EORTC bladder cancer calculator validated across all patient populations?
The EORTC model was derived from 2,596 patients enrolled in seven European trials conducted largely before modern BCG maintenance regimens were standardized. External validation studies report moderate predictive accuracy, with c-statistics typically in the 0.60-0.65 range. Performance may differ in populations with high BCG compliance, variant urothelial histology, or prior BCG exposure. The model performs most reliably in primary Ta and T1 urothelial carcinoma, and results should always be interpreted within the full clinical context of each individual patient.
How frequently should high-risk NMIBC patients undergo cystoscopy based on EORTC results?
Patients classified as high or very-high risk by the EORTC scoring system should undergo surveillance cystoscopy every three months for the first two years following transurethral resection of the bladder tumor (TURBT), per EAU guidelines. This interval extends to every six months in years three and four, and annually thereafter if no recurrence is detected. Upper urinary tract imaging every one to two years is also recommended for high-risk patients due to the elevated risk of synchronous upper tract urothelial carcinoma.